Editas Medicine unveiled new preclinical data for its investigational therapy EDIT-401, focusing on durability in treating hyperlipidemia, at AHA2026. The findings suggest that EDIT-401 could ...
Editas Medicine has announced its financial results and business developments for the third quarter of 2026. The update was shared through an official press release and includes information on ...
Editas Medicine announced that it will present new preclinical data on EDIT-401, its lead in vivo development candidate, at this year’s American Heart Association Scientific Sessions in Chicago. ...
Editas Medicine has revealed plans to present scientific posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress. The company also announced its participation in an ...
Editas Medicine has received authorization to begin its first in human clinical trial of EDIT-401, targeting patients with hyperlipidemia. This development marks a notable milestone for the ...
Editas Medicine has announced the appointment of Dan Ory, M.D., as its new chief medical officer. The company shared the leadership change in an update, adding that additional details are ...
Editas Medicine has released its financial results for the second quarter of 2026, alongside a series of business updates. The company outlined its progress across therapeutic areas, including ...
Editas Medicine employees recently took part in the annual J.P. Morgan Corporate Challenge, strengthening relationships beyond the workplace. The event provided staff with an opportunity to ...
Editas Medicine is preparing to deliver a keynote lecture at the upcoming European Congress on Biotechnology, focusing on the evolution of genetic medicines. The presentation, titled 'A Walk ...
Editas Medicine announced that its President and CEO, Gilmore O’Neill, will participate in the upcoming Longwood Healthcare Leaders MIT CEO 2026 Meeting. He is scheduled to join industry peers ...
Editas Medicine has updated the scheduled presentation time for its upcoming appearance at an investor conference. The company directed stakeholders to its full press release for detailed ...
Editas Medicine presented new preclinical data this week at EASCongress2026, focusing on the progress of its lead in vivo development candidate, EDIT-401. The company provided details supporting ...
Editas Medicine will attend the 94th European Atherosclerosis Society Congress in Athens next week, where it plans to present new preclinical findings on its lead in vivo development candidate, ...